Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Healthcare Biotechnology

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.

TSXV:ARCH - Post by User

Arch Biopartners Inc

Bullboard Posts

Comment by Riverfolkon Apr 23, 2020 5:44pm

40 Views

Post# 30947102

RE:COVID 19 NEWS - ARCH SUBMITS PHASE 2 APPLICATION TO HEALTH C

As a result of clinical interest to support the Phase II trial in the United States, Arch will be preparing an application to the U.S. Food and Drug Administration as well as other authorities within the American hospital system.

This news release is full of bullish information IMHo

Bullboard Posts

3 Mid-Sized Stocks to Consider This Season